The Role of Systemic Therapy in Advanced Cutaneous Squamous Cell Carcinoma

Caitlin P. McMullen, Thomas J. Ow

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Systemic therapy for patients with head and neck cutaneous squamous cell carcinoma (HNCSCC) generally is used for patients with advanced disease and most often employed for patients in the palliative setting when disease is unresectable and/or widely metastatic. Cytotoxic agents and epidermal growth factor receptor pathway targeted therapy have been utilized most commonly, with few clinical data to support their efficacy. Adjuvant postoperative chemoradiation with platinum has been called into question based on recent data. Programmed cell death protein 1 receptor immune checkpoint inhibitors have demonstrated profound activity in HNCSCC, and cemiplimab and pembrolizumab now are approved for use for unresectable/metastatic disease.

Original languageEnglish (US)
Pages (from-to)343-355
Number of pages13
JournalOtolaryngologic Clinics of North America
Issue number2
StatePublished - Apr 2021


  • Cancer treatment protocols
  • Immunotherapy
  • Skin cancers
  • Squamous cell cancer

ASJC Scopus subject areas

  • Otorhinolaryngology


Dive into the research topics of 'The Role of Systemic Therapy in Advanced Cutaneous Squamous Cell Carcinoma'. Together they form a unique fingerprint.

Cite this